Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, et al.
Journal of Affective Disorders (2020) Vol. 276, pp. 570-575
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?
Diego A. Pizzagalli
American Journal of Psychiatry (2022) Vol. 179, Iss. 7, pp. 458-469
Open Access | Times Cited: 94
The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review
Muhammad Youshay Jawad, Saleha Qasim, Menglu Ni, et al.
Brain Sciences (2023) Vol. 13, Iss. 6, pp. 909-909
Open Access | Times Cited: 36
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Fabrice Jollant, Romain Colle, Thi Mai Loan Nguyen, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 33
Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
Sabrina Wong, Gia Han Le, Lee Phan, et al.
Journal of Affective Disorders (2024) Vol. 356, pp. 684-698
Closed Access | Times Cited: 14
The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
Danica Nogo, Ashitija Jasrai, Haeun Kim, et al.
Psychopharmacology (2022) Vol. 239, Iss. 7, pp. 2011-2039
Closed Access | Times Cited: 32
How well do Cognitive Behavioural Therapy and Behavioural Activation for depression repair anhedonia? A secondary analysis of the COBRA randomized controlled trial
Batool Alsayednasser, Emily Widnall, Heather O’Mahen, et al.
Behaviour Research and Therapy (2022) Vol. 159, pp. 104185-104185
Open Access | Times Cited: 31
A single intravenous administration of a sub-anesthetic ketamine dose during the perioperative period of cesarean section for preventing postpartum depression: A meta-analysis
Qiuwen Li, Saiying Wang, Xi Mei
Psychiatry Research (2022) Vol. 310, pp. 114396-114396
Closed Access | Times Cited: 30
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Dania Akbar, Taeho Greg Rhee, Felicia Ceban, et al.
CNS Drugs (2023) Vol. 37, Iss. 10, pp. 867-881
Closed Access | Times Cited: 18
Changes in white matter microstructure following serial ketamine infusions in treatment resistant depression
Brandon Taraku, Roger P. Woods, Michael Boucher, et al.
Human Brain Mapping (2023) Vol. 44, Iss. 6, pp. 2395-2406
Open Access | Times Cited: 16
Annual Research Review: Puberty and the development of anhedonia – considering childhood adversity and inflammation
Tina Gupta, Kristen Eckstrand, Erika E. Forbes
Journal of Child Psychology and Psychiatry (2024) Vol. 65, Iss. 4, pp. 459-480
Closed Access | Times Cited: 7
Anhedonia in bipolar depression treated with ketamine
Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska, et al.
Bipolar Disorders (2024) Vol. 26, Iss. 4, pp. 356-363
Closed Access | Times Cited: 6
Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
Emily S. Gillissie, Gia Han Le, Taeho Greg Rhee, et al.
Journal of Psychiatric Research (2022) Vol. 158, pp. 209-215
Open Access | Times Cited: 25
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
Neuropharmacology (2022) Vol. 223, pp. 109299-109299
Closed Access | Times Cited: 22
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review
Aleksander Kwaśny, Julia Kwaśna, Alina Wilkowska, et al.
European Neuropsychopharmacology (2024) Vol. 86, pp. 20-34
Closed Access | Times Cited: 5
Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens
Federica Lucantonio, Jacob Roeglin, Shuwen Li, et al.
Neuron (2025)
Open Access
Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression
Alina Wilkowska, Mariusz S. Wiglusz, Maria Gałuszko‐Węgielnik, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 28
Anhedonia as a Core Symptom of Depression and a Construct for Biological Research
Majd Al‐Soleiti, Jennifer L. Vande Voort, Balwinder Singh
FOCUS The Journal of Lifelong Learning in Psychiatry (2025) Vol. 23, Iss. 2, pp. 163-172
Closed Access
Anhedonia in Posttraumatic Stress Disorder: Prevalence, Phenotypes, and Neural Circuitry
Meghan Vinograd, Daniel M. Stout, Victoria B. Risbrough
Current topics in behavioral neurosciences (2021), pp. 185-199
Closed Access | Times Cited: 24
Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression
Aleksander Kwaśny, Wiesław Jerzy Cubała, Adam Włodarczyk
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Aistė Lengvenytė, Robertas Strumila, Émilie Olié, et al.
European Neuropsychopharmacology (2022) Vol. 57, pp. 88-104
Open Access | Times Cited: 15
Pharmacological Treatments for Anhedonia
Matthew Klein, Ariela Buxbaum Grice, Sahil Sheth, et al.
Current topics in behavioral neurosciences (2022), pp. 467-489
Closed Access | Times Cited: 14
Molecular and Medical Aspects of Psychedelics
Adam Wojtas, Krystyna Gołembiowska
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 241-241
Open Access | Times Cited: 8
Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans
Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra, et al.
Psychiatry Research (2024) Vol. 335, pp. 115858-115858
Open Access | Times Cited: 2
The Use of Ketamine for the Treatment of Anhedonia in Depression
Liliana Patarroyo-Rodríguez, Stefanie Cavalcanti, Jennifer L. Vande Voort, et al.
CNS Drugs (2024) Vol. 38, Iss. 8, pp. 583-596
Closed Access | Times Cited: 2
Biomarkers of ketamine's antidepressant effect: An umbrella review
Shakila Meshkat, Roger Ho, Bing Cao, et al.
Journal of Affective Disorders (2022) Vol. 323, pp. 598-606
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top